Accessibility Menu
Cyclopharm logo

Cyclopharm(ASX) CYC

Market CapA$64.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-68%
5 Year-68%
1 Year-42%
1 Month-6%
A$0.51
+0.00%
+0.00Today
Cyclopharm last closing stock price
MetricPriceDate
Last closeAUD 0.512026-09-08
Cyclopharm stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%AUD 0.512026-09-01
1 month-6.42%AUD 0.552026-08-07
3 month-13.56%AUD 0.592026-06-10
Year to date-47.96%AUD 0.982025-12-30
1 year-42.05%AUD 0.882025-09-08
3 year-80.75%AUD 2.652023-09-08
5 year-67.84%AUD 1.592021-09-09
Since inception-68.32%AUD 1.612007-01-18

Cyclopharm Financials at a Glance

Market Cap

A$64.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$64.21M

Net Income (TTM)

-A$31.70M

EPS (TTM)

-A$0.16

P/E Ratio

-3.21

Dividend

A$0.00

Beta (Volatility)

-0.07 (Low)

Price

A$0.51

Volume

6,000

Open

A$0.51

Previous Close

A$0.51

Daily Range

A$0.51 - A$0.51

52-Week Range

A$0.45 - A$1.29

Estimated Earnings Date

Feb 24, 2027

CYC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cyclopharm

Cyclopharm Limited is an international enterprise specializing in the production and global distribution of medical devices and radiopharmaceuticals. The company operates primarily in the Asia Pacific, Europe, and Canada, focusing on two main divisions: Technegas and Molecular Imaging.

Products and Services
  • Technegas segment provides diagnostic apparatus for pulmonary embolism detection
  • Molecular Imaging division offers advanced radiopharmaceutical agents for various medical conditions
  • Distribution of third-party diagnostic imaging products
Growth Outlook
  • Recent quarterly revenue increased to AUD 17.52 million, showing strong demand
  • Expansion into new markets is anticipated to drive future growth
  • Investment in R&D aims to enhance product offerings and market competitiveness
Financial Highlights
  • Trailing twelve months (TTM) revenue of AUD 61.5 million reflects a growing business
  • Current ratio of 3.37 indicates strong short-term financial health
  • Cash and cash equivalents reached AUD 12.25 million, providing liquidity for operations
Cyclopharm Limited is positioned in the healthcare sector, focusing on innovative solutions for diagnostic imaging and radiopharmaceuticals. The company's Technegas and Molecular Imaging divisions cater to critical medical needs, particularly in nuclear medicine. Recent financial performance indicates a positive trajectory, with increasing revenues and a solid current ratio, suggesting a robust operational foundation. The ongoing investment in research and development is expected to further enhance the company's product portfolio, potentially leading to increased market share and profitability. As Cyclopharm continues to expand its global footprint, it remains a noteworthy player in the medical devices industry.
AI Generated • Aug 29, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

109

CEO

James M. McBrayer

Website

www.cyclopharm.com

Headquarters

Kingsgrove, NSW 2208, AU

CYC Financials

Key Financial Metrics (TTM)

Gross Margin

-1.41%

Operating Margin

-51.62%

Net Income Margin

-53.23%

Return on Equity

-62.14%

Return on Capital

-43.26%

Return on Assets

-36.88%

Earnings Yield

-31.15%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$64.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

125.73M

Volume

6.00K

Avg. Volume

143.20K

Financials (TTM)

Gross Profit

A$17.87M

Operating Income

-A$40.98M

EBITDA

-A$31.03M

Operating Cash Flow

-A$31.22M

Capital Expenditure

-A$2.63M

Free Cash Flow

-A$33.85M

Cash & ST Invst.

A$12.25M

Total Debt

A$7.80M

Cyclopharm Performance Analysis

Cyclopharm annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31AUD 23,218,79731.1%
20232023-12-31AUD 26,339,38913.4%
20242024-12-31AUD 27,572,5814.7%
20252025-12-31AUD 32,325,25617.2%
Cyclopharm sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3117.0%
Q22025-06-307.4%
Q42025-12-319.6%
Q22026-06-303.7%
Cyclopharm annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31AUD -0.0727.4%
20232023-12-31AUD -0.05-29.3%
20242024-12-31AUD -0.13152.9%
20252025-12-31AUD -0.1622.0%
Cyclopharm sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3134.0%
Q22025-06-30-34.6%
Q42025-12-31-24.6%
Q22026-06-3015.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$17.52M

+42.7%

Gross Profit

-A$23.96K

+98.5%

Gross Margin

-0.14%

N/A

Market Cap

A$64.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$616.58K

N/A

Employees

104

N/A

Net Income

-A$8.79M

-17.1%

EBITDA

-A$7.62M

-15.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$12.25M

-55.6%

Total Debt

A$7.80M

+40.0%

Accounts Receivable

A$8.57M

+2.9%

Inventory

A$12.05M

+15.9%

Long Term Debt

A$7.32M

+57.3%

Short Term Debt

A$479.01K

-47.7%

Return on Assets

-36.88%

N/A

Return on Invested Capital

-44.86%

N/A

Free Cash Flow

-A$7.88M

-15.8%

Operating Cash Flow

-A$7.69M

-20.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
M7T.AXMach7 Technologies Limited
A$0.28+0.00%
ATX.AXAmplia Therapeutics Limited
A$0.13+0.00%
MVP.AXMedical Developments International Limited
A$0.50+5.26%
CMP.AXCompumedics Limited
A$0.24-4.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$102.89+0.07%
NVDANvidia
$227.68-0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.65+0.05%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$43.78-0.06%

Questions About CYC

What is the current price of Cyclopharm?

Cyclopharm is trading at A$0.51 per share.

What is the 52-week range for Cyclopharm?

Over the past 52 weeks, Cyclopharm has traded between A$0.45 and A$1.29.

How much debt does Cyclopharm have?

As of the most recent reporting period, Cyclopharm reported total debt of A$7.74M.

How much cash does Cyclopharm have on hand?

Cyclopharm reported A$6.63M in cash and cash equivalents in its most recent financial results.

What is Cyclopharm’s dividend yield?

Cyclopharm does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services